The 67th American Society of Hematology (ASH) Annual Meeting & Exposition took place from December 6–9, 2025, in Orlando, Florida, offering both in-person and virtual participation. As the leading global forum for hematology, ASH 2025 brought together clinicians, researchers, and industry experts to present the latest advances in blood cancer research, benign hematologic disorders, emerging therapies, and clinical practice standards. The meeting featured high-impact scientific sessions, educational programs, late-breaking abstracts, and extensive industry exhibits, with core content made available online and on-demand through early 2026, ensuring broad access for the international hematology community.
20 Posts Not to Miss from ASH 2025
In this article, we selected 20 key posts you shouldn’t miss, capturing the most impactful insights, research updates, and expert perspectives shared throughout ASH 2025.
“This UPenn conclusion that “ additional risks related to PROLONGED LYMPHOPENIA including DECREASED survival and a trend toward INCREASED risk of other malignancies “ is a warning cry we have shouting at the top of our lungs! Important for patients and clinicians to recognize.”
“This will change Hematology forever : the milder Aza/Ven combination is more effective and less harmful than the traditional 3+7 chemo regimen in fit AML patients.
Groundbreaking data at ASH2025.”
“Agree with Dr. Landau ASH25 You cannot make a diagnosis of “MGRS” without a renal biopsy. And on a renal biopsy you need to have proof of a specific pathology (see Table) that’s attributable to a monoclonal protein.”
“ASH25 Out in NEJM concurrent with the oral prez, REDIRECTT-1 trial showing Teclistamab + Talquetamab inducing deep and durable responses in true EMD (79% ORR, 53% CR) regardless of organ location and w/ predictable safety profile.”
“ASH25 A most brilliant time spending a few quality moments with Professor Charlie Craddock CBE at ASH discussing the importance of clinical trial networks across the world for rare blood cancers!”
“Grateful to Blood Journal, co-authors, and SWOG for making this down withdex piece possible! Dex 40mg weekly in MMsm induction: Not practical even for trial-enrolled patients Does not improve PFS vs dex Twitter once I’m back from IMS24!”
“Not all menin inhibitors are the same! Incredible presentation by Naval Daver, M.D. – updated results of Enzomenib Mono Tx for R/R NPM1m & KMT2Ar AML. ORR >70% & CR/CRh >40% in KMT2Ar AML with median DOR >12 mos. Privilege to be part of the Enzo dev. In AML.”
“Great presentation Jack Khouri, Cleveland Clinic at ASH25 oral presentation about novel CXCR4 antagonists “ Burixfor “ in combination with propranolol in Multiple Myeloma with excellent PBSC yield and outcomes.”
“ASH Plenary Highlight CLL17 provides definitive comparative data in frontline CLL. Fixed duration venetoclax-obinutuzumab (VO) and venetoclax-ibrutinib (VI) achieved noninferior progression-free survival compared with continuous ibrutinib. Key data: • 3-year PFS: I 81.0%, VI 79.4%, VO 81.1% • 3-year OS remained high across all arms • Safety profiles consistent with known AE patterns • Infection risk notable with CD20 antibodies • For most previously untreated patients, fixed duration targeted therapy emerges as a primary option A landmark trial clarifying optimal frontline strategy in CLL.”
“Menin inhibitors are the new kid on the block for AML. Come learn more about the FDA approval process & what this means for clinical use in our patients ASH, FDA symposium happening today at 4.30 pm.”
“Congratulations to the PARADIGM team! Aza-Ven delivering longer EFS, better responses, smoother journeys to transplant… the data are speaking loudly. Maybe it is finally time to let conventional induction chemotherapy enjoy a well-deserved retirement.”
“Huge congratulations to Kelly Bolton and her lab WashU for an outstanding ASH25 Plenary presentation on reducing therapy-related myeloid neoplasms. TP53 + MN remain one of our greatest challenges, prevention is key. Awesome work!”
“Cheers to the MARROW Consortium on a productive ASH25 – looking forward to the collaboration ahead and so proud of what has been accomplished so far!! Well done to our lead authors beautifully presenting key data on vulnerable populations with myeloid disorders.”
“Sharing some exciting data today at ASH25 poster sessions: 1/3940: Single-cell transcriptomic profiling of extramedullary disease reveals a distinctly aggressive biology, marked by highly proliferative, predominantly MYC-driven states with strong enrichment of EMT programs. This is coupled with suppression of oxidative phosphorylation and broad dampening of key immune signaling pathways. We also observe striking upregulation of CD44, ACTN4, and angiogenesis-related genes, alongside pronounced heterogeneity in therapeutic target expression—underscoring both the biological plasticity and therapeutic challenge of EMD.”
“A powerhouse ASH25 Plenary today: time-limited therapy reshaping CLL, new insights for SCD, a novel DLBCL subtype uncovered, TP53-mutant CHIP challenged, IV iron clarified, and PARADIGM redefining AML induction. Science moving fast, and changing practice. ”
“Chatting with the one and only Amir Fathi at the ASH President’s Reception! Still looking good fresh off his amazing Plenary Presentation!”
“Stop by this evening’s ASH25 poster session to see how early therapeutic intervention in high-risk CCUS is being explored in this TiP (Poster 3160). to the visionary BTC effort and co-investigators.”
“First time at ASH but my friends, mentors, collaborators made me feel welcome, even to a cardiologist! Julia Zhang, my close buddy since our intern Zhuoer Xie my fantastic CHIP collab and friend Dr. Sokol, Moffitt Hem Onc PD and my forever Heme A attending.”
“Shumilov et al – ASCT in Alk+ ALCL – EMBT, 1L and beyond – 282 ASCT (81 1L), 100 alloSCT – 3y PFS 75% 1L, 57% for salvage – PR vs CR no diff – allo, med age 33! 3y PFS 62%, prior ASCT no diff – no. prior lines important ASH2025”
John P. Leonard, MD:
“I had a great conversation with Sam Yamshon from Perlmutter Cancer Center Perlmutter Cancer Center and NYU Langone Health NYU Langone Health about his ASH25 presentation on immunological priming of CAR-T cells with the EZH2 inhibitor tazemetostat in B cell lymphoma.”
15 Posts Not to Miss from ASH 2025, Part 1
Written by Nare Hovhannisyan, MD